PROMISE Score for Malignant Pleural Effusion

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
promise score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–20
  • Intermediate-Low Risk21–30
  • Intermediate-High Risk31–40
  • High Risk41–80
Direct Clinical Answer

The PROMISE Score for Malignant Pleural Effusion calculates predicting 3-month mortality in patients with malignant pleural effusion using clinical and biological parameters. Key inputs include previous chemotherapy. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

Predicts 3-month mortality in patients with malignant pleural effusion using clinical and biological parameters. This validated prognostic tool combines patient characteristics, performance status, laboratory values, and treatment history to provide accurate risk stratification and guide clinical decision-making for patients with malignant pleural effusion.

Clinical Indication

The PROMISE Score for Malignant Pleural Effusion is indicated for bedside clinical practice to support Predicts 3-month mortality in patients with malignant pleural effusion using clinical and biological parameters. This validated prognostic tool combines patient characteristics, performance status, laboratory values, and treatment history to provide accurate risk stratification and guide clinical decision-making for patients with malignant pleural effusion.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Helps guide treatment decisions including pleurodesis, drainage procedures, and palliative care.

Formula & Variables:

Sum of weighted points from: Previous chemotherapy (0-4), Previous radiotherapy (0-2), Hemoglobin level (0-4), WBC count (0-9), CRP level (0-11), ECOG status (0-7), Cancer type (0-6)

Input Parameters

NameTypeRequiredDescription
previous_chemotherapystringYesHistory of previous chemotherapy treatment
previous_radiotherapystringYesHistory of previous radiotherapy treatment
hemoglobinstringYesHemoglobin level in g/dL(g/dL)
wbc_countstringYesSerum white blood cell count in 10⁹ cells/L(×10⁹ cells/L)
crpstringYesC-reactive protein level in mg/L(mg/L)
ecog_statusstringYesECOG Performance Status
cancer_typestringYesPrimary cancer type

Score Interpretation & Guidance

RangeStageDescription
0–20Low Risk3-month mortality <25%
21–30Intermediate-Low Risk3-month mortality 25-50%
31–40Intermediate-High Risk3-month mortality 50-75%
41–80High Risk3-month mortality >75%

Evidence-Based References (EBM)

  • Psallidas I, Kanellakis NI, Gerry S, Thakur N, Bamber J, Dipper A, et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol. 2018;19(7):930-939. doi: 10.1016/S1470-2045(18)30294-8.DOI: 10.1016/S1470-2045(18)30294-8
  • Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098-104. doi: 10.1136/thoraxjnl-2014-205285.DOI: 10.1136/thoraxjnl-2014-205285
  • Yap E, Anderson B, Nair A, Vaska K, Ferland L, Penney B, et al. The role of LENT and PROMISE scores in predicting survival in malignant pleural effusion. Lung. 2022;200(4):459-465. doi: 10.1007/s00408-022-00547-5.DOI: 10.1007/s00408-022-00547-5

Related calculators